Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers

Company Overview - Kyowa Kirin, Inc. is a wholly owned subsidiary of Kyowa Kirin Co. Ltd, focused on developing solutions for rare diseases, particularly in oncology [1][5] - The company has over 70 years of experience in drug discovery and biotechnology innovation, aiming to deliver novel medicines and treatments with life-changing value [7] Industry Context - Cutaneous T-cell lymphoma (CTCL) is a rare form of blood cancer that primarily affects the skin, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes [2][6] - Diagnosis of CTCL can be challenging, often taking patients 2-7 years to receive an accurate diagnosis, which can lead to worse prognoses [2][5] Product Launch - Kyowa Kirin has launched a new staging tool for healthcare providers to assist in the accurate staging of patients with MF and SS, available on PROBEinCTCL.com [1][5] - The tool simplifies the staging process by using up to 20 Yes/No questions and real clinical case imagery, guiding users through the TNMB system [3][4] Clinical Relevance - The staging tool is designed to enhance clinical judgment by translating complex guidelines into a practical assessment, thereby supporting more consistent and informed care [2][3] - The tool is based on established guidelines from the National Comprehensive Cancer Network and recommendations from various oncology organizations [4]